Back

ACEi/ARB treatment in patients with myocardial infarction and preserved left ventricular ejection fraction does not confer a benefit: a target trial emulation

31 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy in coronary artery disease (1) Pharmacotherapy ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Anna Humphreys

Karolinska Institute, Stockholm (Sweden)

3 More presentations in this session

Presentation thumbnail
Long-term efficacy of endotype-based drug therapy on quality of life and symptom management in coronary vasomotion disorders
Ms L. Saccardi (Stuttgart, DE)
Abstract Slides Video
Presentation thumbnail
Spironolactone and coronary atherosclerotic plaque modulation: insights from a serial coronary computed tomography angiography cohort study
Doctor J. Zhang (Chengdu, CN)
Abstract Slides Video
Presentation thumbnail
Heparin pretreatment in patients with ST-segment elevation myocardial infarction: a meta-analysis
Doctor L. Siega Vignut (Trieste, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy in coronary artery disease (1)

The Event

Event poster

ESC Congress 2025

31 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Session
HOT LINE 3
thumbnail
Congress Presentation
ICD in HF: a target trial emulation study
thumbnail
Congress Presentation
Cardiac resynchronization therapy in heart failure: a target trial emulation study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources